Abstract
Fine chemicals companies continue to hone their production technologies, powered by research strategies that increasingly are directed toward specific goals. This new tactic translates into more purposeful exploitation of core chemistries and into targeting specific processes to be invented. Such directed thinking was evident on the exposition floor of Pharmaceutical Ingredients USA (PhIUS) in Philadelphia last month. But it is also a movement that has been maturing for some time. For example, Bayer has begun to receive patents on strategic construction of particular substitution patterns on the pyrimidine nucleus. Bayer also has developed versatile syntheses of quinolone antibacterials. And chemists at Novartis have made significant progress in devising asymmetric hydrogenations of the carbon-nitrogen double bond—a task that has proven much more difficult than enantioselective reductions of carboncarbon double bonds or carbonyl groups. Meanwhile, research at NSC Technologies, Mount Prospect, Ill., has re...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
